Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01662362 · ClinicalTrials.gov registry record · NA
Abbott ESA Chagas Assay Post-Market Study
A NA study, sponsored by Abbott Diagnostics Division.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT01662362: Completed NA study, sponsored by Abbott Diagnostics Division.
NCT01662362 is a NA study that has completed, run by Abbott Diagnostics Division. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01662362, a NA study, has completed, sponsored by Abbott Diagnostics Division.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
The study is conducted to meet an FDA post market commitment to collect and report data on the performance of the ESA Chagas assay. A minimum of 50 donor specimens that are FDA-licensed ABBOTT PRISM Chagas repeatedly reactive (RR)will be tested with the ABBOTT ESA Chagas assay. In addition, minimum of 300 ABBOTT PRISM Chagas nonreactive (NR) unidentified donor specimens will be tested with ABBOTT ESA Chagas assay.
Interventions
- DEVICE Testing Donor Specimens with ESA Chagas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-12 |
| Phase | NA |
What the finished NCT01662362 record still lists
NCT01662362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Testing Donor Specimens with ESA Chagas is the first listed.
NCT01662362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01662362 about?
NCT01662362 is a clinical study titled "Abbott ESA Chagas Assay Post-Market Study". The study is conducted to meet an FDA post market commitment to collect and report data on the performance of the ESA Chagas assay. A minimum of 50 donor specimens that are FDA-licensed ABBOTT PRISM Chagas repeatedly reactive (RR)will be tested with the ABBOTT ESA Chagas assay. In addition, minimum ...
What is the current status of trial NCT01662362?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2012-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01662362?
The interventions under investigation include: Testing Donor Specimens with ESA Chagas (DEVICE).
Who is sponsoring clinical trial NCT01662362?
This trial is sponsored by Abbott Diagnostics Division, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01662362's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia